Article
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2011
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, LaBonte M J, Wilson P M, Gordon M A, Hu-Lieskovan S, Mauro D J, Langer C, Rowinsky E K, Lenz H-J
Abstract excerpt
PURPOSE: recent studies have found that KRAS mutations predict resistance to monoclonal antibodies targeting the epidermal growth factor receptor in metastatic colorectal cancer (mCRC). A polymorphism in a let-7 microRNA complementary site (lcs6) in the KRAS 3' untranslated region (UTR) is associated with an increased cancer risk in non-small-cell lung cancer and reduced overall survival (OS) in oral cancers. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.